EUGENE, Ore., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cascade Prodrug Inc. (Cascade), a private preclinical-stage biotechnology company focused on developing novel small molecule therapeutics targeting hypoxia, today announced a poster presentation highlighting preclinical data for it's lead candidate CPD100Li at the SITC 2023 Annual Meeting, being held November 3-5 in San Diego, CA.

Poster details are as follows:

Title: Modulating the tumor microenvironment via hypoxia activated prodrug CPD100Li induced cell death synergistically enhances anti-CTLA-4 immunotherapy
Poster / Abstract Number: 1086
Date / Time: November 4, 2023 / 9:00 a.m. - 8:30 p.m. PT
Location: Exhibit Hall Exhibit Halls A and B1 – San Diego Convention Center

Full text of the abstract will be ...

Full story available on Benzinga.com